CMV Antigens

Size: 100 μg/vial
Price: $ 275.00
In Stock: 23
Need More?
Request additional quantity

Donor Details

Anticoagulant : Unknown

Additional Product Information:

CMV antigens are enriched from a culture of CMV infected human fibroblasts by centrifugation on a sucrose gradient. There are multiple viral proteins present.

Need something more unique?
Submit a custom request.

About Whole Antigens

Our whole antigen products are proteins and viral lysates that stimulate in vitro immune responses from all donors who have been sensitized to the antigen. This eliminates the choice of a dominant peptide or protein allowing you to use one antigen for all donors.

The majority of the U.S. population is immunized with tetanus toxoid and 30–40% of the population is positive for cytomegalovirus (CMV), making these two antigens good choices for use in recall assays.

We offer various antigens to stimulate cells, all tested for bioactivity using our PBMC. Our three recall antigens can be used to study different types of immunological memory: cytomegalovirus (CMV), tetanus, and M1.

CMV Antigens: PBMC activation by CMV antigen usually indicates a donor who is seropositive for CMV, though we have observed stimulation of PBMC from seronegative donors. CMV establishes a latent infection and is contained by the immune system in healthy CMV positive donors. This results in a relatively large population of CMV-reactive T lymphocytes, both CD4+ and CD8+.

Tetanus Antigens: The tetanus antigen is complexed with alum but stimulates PBMC proliferation well. Most individuals are vaccinated with this antigen and therefore have an immune response to it. The magnitude of the response varies among donors depending on their immune status, age, and time since last tetanus vaccination. Because of the presence of alum, this preparation may not be suitable for uses other than in vitro immune responses.

M1 Antigens: The M1 peptide is an immunodominant epitope from influenza virus, but only for donors who express HLA-A*0201. We have observed reactivity to this antigen preparation, but only after a 7–10 day culture period. Unlike CMV, influenza virus is cleared from the body following infection, so the immune response to the antigen wanes after infection. This antigen will only stimulate CD8+ T cells, not CD4+ T cells.

As we add antigen-specific T cells to our catalog, we also add their cognate peptide antigens.